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Combining two antitubercular drugs, clofazimine and 4-aminosalicylic acid, in order to improve clofazimine 
aqueous solubility and 4-aminosalicylic acid thermal stability 
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Abstract: Four forms of a salt combining two antitubercular drugs, clofazimine and 4-aminosalicylic acid, are reported 
and the crystal structure of two of these forms are described. TG/DSC analysis of all four forms demonstrate an increase 
in the temperature at which degradation (upon decarboxylation) occurs in comparison to pure 4-aminosalicylic acid.   
Water solubility evaluation indicates a significant increase of the amount of clofazimine detected in water (10.26 ± 0.52 
µg/mL for form I, 12.27 ± 0.32 µg/mL for form II, 7.15 ± 0.43 µg/mL for form III and 8.50 ± 1.24 µg/mL for form IV ) in 
comparison to pure clofazimine (0.20 ± 0.03 µg/mL). 
Keywords: clofazimine, 4-aminosalicylic acid, salts, solid-state, polymorph, differential scanning calorimetry, 
thermogravimetric analysis, solubility.
Introduction 
Tuberculosis (TB)1 is an infectious disease caused by 
Mycobacterium tuberculosis (M.tb) which is still among the 
top causes of death worldwide1. Even if drug susceptible 
tuberculosis is curable with a two months treatment 
comprising four first-line antibiotics (rifampicin, isoniazid, 
pyrazinamide and ethambutol) followed by four months 
continuation phase with isoniazid and rifampicin2, multidrug 
resistant (MDR) and extensively drug resistant (XDR) 
strains of M. tb have emerged because of bad compliance 
or inappropriate use of antitubercular drugs.  
In this context, N,5-bis(4-chlorophenyl)-3-propan-2-
yliminophenazin-2-amine (clofazimine, CFZ, Fig. 1a), an 
antimicrobial and anti-inflammatory agent has been 
selected to be part of the shortened Bangladesh regimen 
against MDR tuberculosis3,4. Clofazimine is also 
recommended by the World Health Organization (WHO) as 
a group B agent for the treatment of MDR and XDR 
tuberculosis5. Belonging to the Biopharmaceuticals 
Classification System class II (BCS II),  clofazimine 
                                                          
1 Abbreviations: TB: tuberculosis, M.tb: Mycobacterium 
tuberculosis, MDR: multi drug resistant, XDR: extensively drug 
resistant, CFZ: clofazimine, PAS: 4-aminosalicylic acid, GI: gastro-
intestinal, FaSSIF/FeSSIF/FaSSGF: Fasted-state simulated 
intestinal fluid/ Fed-state simulated intestinal fluid/ Fasted-state 
simulated gastric fluid, LAG: liquid-assisted grinding, DVS: 
dynamic vapour sorption. 
This article contains supplementary material available from 
the authors by request or via the internet. Available 
bioavailability is however limited by its low aqueous 
solubility (<0.001 mg/L 6,7). Several strategies have been 
adopted to improve clofazimine solubility  e.g. the 
preparation of inclusion complexes with cyclodextrins or 
cucurbit[7]uril8–10, of nanoparticules or 
nanosuspensions11,12, of amorphous solid dispersion13 or 
the co-administration with lipid vehicles14.  Another 
alternative is to take advantage of the basicity of CFZ to 
prepare salts15–18. 
According to the WHO, 4-amino-2-hydroxybenzoic acid (4-
aminosalicylic acid, PAS, Fig. 1b) is classified as a group C 
drug for the treatment of multidrug resistant tuberculosis5. 
This compound is a prodrug mimicking 4-aminobenzoic 
acid, the substrate of dihydropteroate synthase19. PAS is a 
BCS III20 compound with a reported aqueous solubility of 
3.22 g/L at 30 °C6. It is however known to be unstable at 
low pH as it can decarboxylate to 3-aminophenol21 through 
the formation of the PAS zwitterion (isoelectric point of 
2.71)21. In the solid-state, the crystalline powder can also 
decompose under exposition to moisture or heat22,23. The 
supplementary materials: Comment on the selection of 
solvents. Tables of experimental details and of hydrogen bond 
parameters; observed, calculated and difference pattern from 
structure solution of CFZNH+-PAS- form II; description of 
CFZNH+-PAS--MeCN solvate; variable temperature PXRD 
patterns, PXRD patterns of the crystalline phase recovered after 
TG/DSC analysis; typical HPLC chromatograms. 
sodium and calcium salts of PAS are however reported to 
be more stable than the free acid24. Moreover PAS salts 
have also been reported to reduce the gastro-intestinal (GI) 
side effects associated to PAS25,26. More recently, gastro-
resistant caps avoiding PAS exposition to the gastric acidic 
medium and aiming at further diminishing these GI effects 
have been commercialized26. 
The association of CFZ and PAS is reported for the 
treatment of XDR-TB27,28. Zhang et al.29 have further shown 
that PAS enhanced CFZ activity in vitro and Lu et al.30 have 
even shown a synergistic effect between both drugs. 
Similarly, an alternative formulation consisting of salts 
combining CFZ with PAS could potentially improve 
clofazimine solubility and PAS stability. The present study 
reports on the preparation of CFZNH+-PAS- salts that were 
characterized in terms of thermal stability and aqueous 
solubility. 
Materials and Methods 
Materials 
Clofazimine and 4-aminosalicylic acid were purchased 
from TCI Europe and Sigma Aldrich respectively. 
Acetonitrile, ethanol and ethyl acetate were used without 
further purification as crystallization solvents. 
FaSSIF/FeSSIF/FaSSGF powder was purchased from 
Biorelevant (London, UK). 
Salts preparation 
Clofaziminium - 4-aminosalicylate (form I, II and III) were 
prepared by liquid-assisted grinding (LAG) of equimolar 
amount of CFZ (75.0 mg, 0.158 mmol) and PAS (24.3 mg, 
0.158 mmol) in presence of 30 µL of MeCN (CFZ/PAS 1/1 
LAG MeCN) (form I obtained after drying the powder), 
EtOH (CFZ/PAS 1/1 LAG EtOH, form II) or EtOAc 
(CFZ/PAS 1/1 LAG EtOAc form III). See the ESI for 
comment about the choice of the solvents. Grinding 
experiments were performed in 2 mL Eppendorf tubes®, 
filled with seven stainless steel balls of 1 mm diameter and 
one ball of 3 mm diameter. Ball milling was performed for 
90 minutes at 30 Hz using a Retsch Mixer Mill 400 
apparatus and samples were homogenized every 30 
minutes. Single-crystals were obtained by recrystallization, 
at room temperature (293-298 K), of the CFZ/PAS 1 :1  
ground product with MeCN (CFZ/PAS 1/1 LAG MeCN) in a 
mixture of MeCN and MeOH (for form I) or in MeCN (for 
CFZNH+-PAS--MeCN (1:1:1) solvate). Form IV is obtained 
by slurrying equimolar amount of CFZ (75.0 mg, 0.158 
mmol) and PAS (24.3 mg, 0.158 mmol) in water (powder 
was recovered by centrifugation and then oven-dried at 
60°C for one night). 
Single-crystal X-ray diffraction (SCXRD) 
SCXRD data were collected with an Oxford Diffraction 
Gemini Ultra R equipped with a Ruby CCD detector. Full 
data sets were collected with Cu Kα (𝜆 = 1.54184 Å) 
radiation at 295 and 100 K for form I and at 100 K for 
CFZNH+-PAS--MeCN (1:1:1) solvate. Analytical numeric 
absorption correction (using a multifaceted crystal model 
based on expressions derived by R.C. Clark & J.S. Reid31), 
followed by empirical absorption correction (using spherical 
harmonics, implemented in SCALE3 ABSPACK scaling 
algorithm) were performed within CrysAlis PRO32. 
Structure was solved by the dual-space method 
implemented by SHELXT33 within Olex234. Refinement by 
the least-square method implemented by SHELXL35 was 
performed within ShelXle36. Non hydrogen atoms were 
refined anisotropically while hydrogen atoms were refined 
as riding atoms with isotropic displacement parameter set 
to 1.2 times that of the parent atom (1.5 times for methyl 
and OH groups). In the structures determined at 100 K, 
hydrogen atoms implied in strong H-bonds were located in 
Fourier map and refined (except for H atoms of PAS- in the 
structure of form I because this anion is disordered over 
three positions). Structure visualization was performed 
within Mercury37. 
High-resolution powder X-ray diffraction and structure 
solution. 
High-resolution PXRD pattern of form II was collected at 
295 K in transmission mode with a STOE MP diffractometer 
(Cu Kα1 radiation, 𝜆 = 1.54059 Å) between 4 and 40° 2𝜃 
angle, with a step size of 0.15°. Sample was filled in a 0.7 
mm diameter thin-wall glass capillary. Indexation was 
performed within F.O.X version 2017.2 38. Intensities were 
extracted by the Le Bail method implemented within F.O.X. 
and structure solution was performed by a direct-space 
method within the same program using clofaziminium and 
4-aminosalicylate geometries extracted from SCXRD data. 
Structure was refined within TOPAS V6 39, using rigid body 
approach.  
PXRD data were collected with the same diffractometer in 
transmission mode (transmission scan mode) from 4 to 40° 
2𝜃 angle after solubility and slurry experiments. 
Powder X-ray diffraction (PXRD) 
PXRD data were collected with a PANalytical X’PERT PRO 
Bragg-Brentano diffractometer, using Cu Kα (𝜆 = 1.54184 
Å) radiation (2𝜃 angle ranging from 4 to 40° with a step size 
of 0.0167°).   
Variable-temperature PXRD data were collected at 25°C, 
from 30 to 150°C (data collected every 10°C), at 175 and 
200°C with the same diffractometer equipped with an 
Anton-Paar TTK 450 heating system. 
 
Figure 1. Molecular diagram of (a) clofazimine (CFZ) and 
(b) 4-aminosalicylic acid (PAS). 
TGA/DSC 
Thermal stability of the four forms was evaluated with a 
TGA/DSC3+ apparatus (Mettler Toledo). Solid samples 
were analysed in open aluminium pans (100 µL) from 25 to 
300°C (at a 10 °C/min scanning rate) under a nitrogen flow 
(80 mL/min). Results were analyzed with the STARe 
software (version 16.20). 
Water solubility evaluation 
Solubility of CFZ, PAS and CFZNH+-PAS- salt (forms I to 
IV) was evaluated in type I water, by wetting an excess 
amount of powder (10-20 mg) in 2.0 mL type I water at 25°C 
(Heidolf incubator 1000) and under agitation at 900 rpm 
(Heidolf titramax 1000 platform shaker). Experiments were 
performed in triplicate. After 24 hours, the samples were 
centrifuged at 13000 rpm (eppendorf centrifuge 5430R, 
equipped with a FA-45-24-11 rotor) for 15 minutes, the 
supernatant was recovered and centrifuged again (15 
minutes, 13000 rpm). After second centrifugation, the 
supernatant was diluted twice with MeCN. Solubility was 
evaluated by an HPLC method performed with a Zorbax SB 
C18 (3.5 µm, 3 x 100 mm) column heated to 40°C and 
connected on an Agilent 1100 series HPLC system using 
UV detection at 280 and 490 nm. Gradient elution was 
performed with mobile phase A (trifluoroacetic acid 0.1%) 
and mobile phase B (MeCN) at a flow rate of 0.5 mL/min. 
Gradient started at 15% B and ramped up to 70% B in 0.5 
minute. This solvent ratio was maintained for 6.5 minutes 
before returning to 15% B for 6 minutes to re-equilibrate the 
column. The injection volume was 5 µL. Calibration was 
performed with samples prepared in MeCN/water 1:1 (in 
volume) with concentrations ranging from 16.6 to 0.06 
µg/mL for CFZ and from 80 to 1.25 µg/mL for PAS. pH of 
the salt solutions (forms I, II, III and IV) was measured after 
first centrifugation and, in all cases, it was comprised 
between 4.5 and 4.9. 
Stability in Fasted-state simulated gastric fluid (FaSSGF) 
Propensity of CFZNH+-PAS- to undergo anion exchange in 
gastric fluid was evaluated by dispersing an excess amount 
of each form in FaSSGF. After 30 minutes, the PXRD 
pattern of the remaining solid was collected with a STOE 
MP diffractometer. Fasted-state simulated gastric fluid was 
prepared by solubilisation of 0.0597 g of 
FaSSIF/FeSSIF/FaSSGF powder in 1.0 L of a NaCl (1.999 
g/L) solution adjusted with HCl at pH 1.6.  
Relative stability of the four forms 
Relative stability of the four forms was evaluated by  
competitive slurry experiments in water at 22°C. Mixtures 
of two forms (I and II, I and III, I and IV, II and III, II and IV 
and III and IV) were suspended in water for 14 days. The 
solid phase was then recovered and analyzed in PXRD.  
 
Evaluation of CFZNH+-PAS- salts hygroscopicity 
Dynamic vapour sorption (DVS) analyses were performed 
on a Q5000 SA apparatus (TA instruments) at 25°C with 
nitrogen as flow gas (50 mL/min). Solid samples (7-15 mg) 
were placed in platinum crucible (empty crucible used as a 
reference) and inserted in a temperature and humidity 
controlled chamber. Samples were first dried at 40°C for 1 
hour and then exposed to variable relative humidity (10 to 
90%) at 25°C. Equilibrium was considered to be reached 
when no weight change is observed for two hours of 
exposure or if it is less than 0.010 mg/min. 
Results  
Forms I to III of CFZNH+-PAS- salt were prepared by liquid-
assisted grinding. PXRD patterns of the ground powders 
were compared to the one of the starting materials and in 
each case a new crystalline phase was identified (Fig. 2).  
Single-crystals were obtained for form I (data were 
collected at 295 K and 100 K) and for a solvated salt 
(CFZNH+-PAS--MeCN (1:1:1), data collected at 100 K). 
Structure of form II was determined from powder data. Both 
forms (I and II) crystallize in 𝑃1̅ triclinic space group and 
their asymmetric units contain one clofaziminium cation 
(CFZNH+) and one 4-aminosalicylate anion (PAS-) (Table 
S1). 
Form III was first identified during competitive slurry of 
forms I and II in water and could be successfully obtained 
by liquid-assisted grinding of clofazimine with 4-
aminosalicylic acid in presence of EtOAc. Form IV was first 
identified after solubility evaluation of form I and could be 
obtained by slurrying clofazimine and 4-aminosalicylic acid 
in water (Fig. 2). Despite several attempts, up to now, 
structures of forms III and IV could not be determined. 
 
Figure 2. PXRD pattern of, from bottom to top: CFZ, PAS 
and (a) CFZ/PAS 1/1 LAG MeCN and calculated pattern of 
CFZNH+-PAS- form I at 100K and 295K, (b) CFZ/PAS 1/1 
LAG EtOH (form II), (c) CFZ/PAS 1/1 LAG EtOAc (form III) 
and (d) CFZ/PAS 1/1 slurry H2O (form IV). 
 
Polymorph I 
Crystals were dried at room temperature before SCXRD 
data collection. PAS- is disordered over 3 positions with 
respective occupancy (at 100K) of 0.493, 0.199 and 0.307 
(disorder identified by letters A, B and C in atom labelling). 
Strong charge-assisted hydrogen bonds are observed 
between CFZNH+ cation and PAS- anion (N4+-H⋯O1A-, 
N3-H⋯O1A-, Fig. 3a and Table S2). Other H-bond 
interactions are presented in Table S2.   
Clofaziminium cations are stacked in a head to tail fashion 
(centroid-centroid distance of 3.672(2) Å, orthogonal 
projection distance of 3.519(1) Å and horizontal 
displacement of 1.046 Å, Fig. 3b). C-H⋯ 𝜋 interactions are 
further observed between CFZNH+ cation and PAS- anion 
(H26C⋯centroid distance of 2.68 Å, orthogonal projection 
distance of 2.68 Å, C26⋯centroid distance of 3.643(9) Å 
and C26-H26C⋯ 𝜋 angle of 78 °, Fig. 3 c). Interestingly 
powder obtained just after LAG in presence of MeCN does 
not correspond to CFZNH+-PAS- form I. This phase is 
however unstable at room temperature and spontaneously 
converts to form I as indicated by PXRD pattern measured 
on freshly prepared powder and after one week of storage 
at room temperature (Fig. 2). 
Polymorph II 
CFZNH+ and PAS- interact through charge-assisted H-
bonds (N4+-H⋯O1A-, N3-H⋯O1A-, Fig. 3d) and Table S2). 
Clofaziminium cations are stacked in a head to tail fashion 
(centroid-centroid distance of 3.760(16) Å, orthogonal 
projection distance of 3.682(13) Å and horizontal 
displacement of 0.767 Å, Fig. 3e). Two C-H⋯ 𝜋 interactions 
are observed between CFZNH+ cation and PAS- anion 
(H26B⋯centroid distance of 2.95(9) Å, orthogonal 
projection distance of 2.81 Å, C26⋯centroid distance of 
3.85(8) Å and C26-H26B⋯ 𝜋 angle of 78 ° as well as  
H4⋯centroid distance of 2.63(8) Å, orthogonal projection 
distance of 2.44 Å, C4⋯centroid distance of 3.48(8) Å and 
C4-H4⋯ 𝜋 angle of 84 °, Fig. 3f). Structure of this second 
form of CFZNH+-PAS- was determined from PXRD data 
collected on a powder of CFZ/PAS 1/1 LAG EtOH (Table 
S1). Observed, calculated and difference patterns are 
shown in supplementary information (Fig. S1). 
Thermal analysis  
TG/DSC analysis performed on a freshly prepared powder 
of CFZ/PAS 1/1 LAG MeCN (Fig 4a) suggests that this 
phase is solvated as a weight loss (associated with a wide 
endotherm on the DSC curve (onset 51°C)) is observed 
from 25°C to around 95°C. This assumption has been 
confirmed by the determination of the crystal structure of 
CFZNH+-PAS--MeCN (1:1:1) solvate (Fig. S2 and Tables 
S1 and S2). A small exothermic event, not associated with 
any weight loss, is observed at 129°C and, at 215°C, 
melting occurs, immediately followed by degradation 
(probably associated with PAS decarboxylation).  
A variable-temperature PXRD experiment performed on 
freshly prepared powder of CFZ/PAS 1/1 LAG MeCN 
indicates the formation of CFZNH+-PAS- form I upon 
heating (Fig. S3). Then, between 130 and 150°C, a 
transformation occurs. Actually, a partial conversion of form 
I to form II is observed upon heating. A kinetically controlled 
process is suspected for this conversion and exact 
condition of conversion could not be determined (Figs. S3 




Figure 3. Crystal structures of CFZNH+-PAS- forms I (left) and II (right). Asymmetric unit and labelling (top), stacking of 
CFZNH+ cations (centroids (red) and planes (blue) calculated with C5, C6, N1, N2, C11 and C12 atoms) (middle) and C-
H⋯π interaction between CFZNH+ and PAS- (centroids calculated with C29, C30, C31, C32, C33 and C34 atoms (position 
A of PAS considered in form I) (bottom). 
 
A new TG/DSC analysis (Fig. 4b) performed on powder 
corresponding to form I (CFZ/PAS LAG MeCN after one 
week of storage at room temperature) does not present any 
weight loss between 25 and 95°C confirming complete 
phase transformation from a solvate to form I in these 
conditions. A small exothermic event is observed at 126°C 
(consistent with phase transformations identified by 
variable temperature PXRD) before melting and 
degradation at 217°C. 
 
Figure 4. TGA (dashed blue) and DSC (plain red) curves of 
(a) CFZ/PAS 1/1 LAG MeCN (powder freshly prepared), (b) 
CFZNH+-PAS- form I, (c) CFZNH+-PAS- form II, (d) 
CFZ/PAS 1/1 LAG EtOAc (form III), (e) CFZ/PAS 1/1 slurry 
H2O (form IV) and (f) PAS. 
In Fig. 4c, thermal stability of form II was evaluated by 
TGA/DSC. Results indicated that this form is stable up to 
210°C, temperature at which melting and degradation 
occur. 
Thermal analysis of form III (Fig. 4d) reveals an 
endothermic event (162°C), corresponding to a phase 
conversion from form III to form II (Figure S5), before 
melting and degradation at 209°C. 
TG/DSC analysis of form IV reveals the presence of a small 
endotherm at 202°C (associated to a 4% weight loss). This 
event is followed by a second endotherm associated to 
melting and further degradation of the phase at 214°C.  
CFZNH+-PAS- behaviour in solution 
Solubility of CFZ, PAS, CFZNH+-PAS- (forms I to IV) was 
studied in water at 25°C by an HPLC method. Results 
indicate that after 24h of dispersion in water, only 0.20 ± 
0.03 µg/mL of clofazimine is released in solution (Fig. 5).  
PAS solubility could not be determined because PAS 
degrades in water (two peaks are observed on the 
chromatogram (Fig. S6)). Such degradation is not 
observed for CFZNH+-PAS- salts (forms I to IV). 
 
Figure 5. Amount of CFZ (red) and PAS (blue) released 
after 24h in water from CFZ and the four salts (forms I to 
IV). 
 
 All four forms present a significant increase of CFZ 
solubility after 24h in water (Fig.5). Indeed, the amount of 
solubilized CFZ reaches 10.26 ± 0.52 µg/mL (50-fold 
improvement), 12.27 ± 0.32 µg/mL (60-fold solubility 
improvement), 7.15 ± 0.43 µg/mL (36-fold improvement) 
and 8.50 ± 1.24 µg/mL (42-fold improvement) from 
CFZNH+-PAS- forms I to IV respectively. The amount of 
solubilized PAS is 15.94 ± 0.55 µg/mL, 11.70 ± 0.17 µg/mL, 
21.47 ± 1.37 µg/mL and 18.47 ± 3.15 µg/mL from forms I to 
IV respectively.  
PXRD analysis of the remaining powder (after 24h 
dispersion in water) indicates that CFZ does not undergo 
any crystalline phase change, CFZNH+-PAS- forms II, III 
and IV remain stable in water for 24h, while form I converts 
to a mixture of form III and form IV. PAS degradation is not 
observed on PXRD pattern collected after solubility 
evaluation of PAS (Fig.6a). This could be explained by the 
high aqueous solubility (26.29 g/L at 20°C6) of the PAS 
degradation product, 3-aminophenol, in water. 
 
Figure 6. PXRD patterns, (a) of CFZ, PAS, CFZNH+-PAS- 
forms I, II, III and IV before and after dispersion in water 
and (b) of CFZNH+-Cl- (calculated pattern), CFZ, CFZNH+-
PAS- (forms I to IV) after dispersion in FaSSGF, and 
powder patterns of CFZNH+-PAS- (II, calculated) and of 
form III. 
 
Bannigan et al.16 reported anion exchange and CFZNH+Cl- 
precipitation after dispersion of CFZ salts in simulated 
gastric fluids. The propensity of CFZNH+-PAS- for anion 
exchange was investigated by a slurry experiment of all 
four forms in FaSSGF. Powders recovered after dispersion 
of form I or IV correspond to CFZNH+Cl-, while the ones 
recovered after dispersion of form II or III in FaSSGF 
correspond to a mixture of CFZNH+Cl- with CFZNH+-PAS- 
(form II or III respectively) (Fig. 6b). Those data are 
consistent with what is reported in literature16 and indicate 
rapid anion exchange and precipitation of the hydrochloride 
salt of clofazimine. 
Relative stability of the four forms 
Competitive slurry experiments of forms I and II, of forms I 
and III as well as of forms II and III lead to form III (Fig. 7). 
This indicates that both forms I and II are less stable than 
form III in water. Relative stability of forms I and II could not 
be determined as both are metastable (conversion to form 
III is already achieved after 48h). All competitive slurry 
experiments implying form IV lead to form IV indicating that 
this is the most stable one in water (Fig. 7). The relative 
stability in water at 22°C can thus be established as 
CFZNH+-PAS- (I), CFZNH+-PAS- (II) < CFZNH+-PAS- (III) < 
CFZNH+-PAS- (IV). 
 
Figure 7. PXRD patterns of the solid phases recovered 
after 14 days of competitive slurry experiments of forms I 
and II, forms I and III, forms I and IV, forms II and III, forms 
II and IV and of forms III and IV compared to the powder 
patterns of forms I, II, III and IV. 
 
Evaluation of CFZNH+-PAS- salts water sorption 
Dynamic vapour sorption analyses were performed on the 
four forms identified. No deliquescence or significant water 
uptake was observed (Fig. 8) except for form I that 
reversibly absorbs around 3% water at 90% humidity (Fig. 
8a). Such a 3% water absorption may correspond to a 
monohydrated (calculated water content of 2.8%) form of 
the salt. Besides, the isotherm hysteresis (Fig. 8a) 
evidences the existence of a hydrated form of CFZNH+-
PAS- (I). 
 
Figure 8. Sorption isotherms (adsorption and desorption) 
of CFZNH+-PAS- form I (a), form II (b), form III (c) and 
form IV( d). 
 
Discussion 
Thermal analyses of the four identified forms indicate that 
form I undergo a phase conversion (between 120 and 
150°C), followed by melting at 215°C. Form III converts to 
form II, which melts at 209°C, upon heating. Thermal 
behaviour of form IV is more complicated as a small 
endotherm associated to a 4% weight loss is observed at 
202°C before melting at 214°C. A 2.9% weight loss would 
be expected for a monohydrate, however the high 
temperature at which the 4% weight loss is observed 
suggests that this phase does not correspond to an 
hydrated form of a clofaziminium 4-aminosalicylate salt.  
For all forms identified, melting is immediately followed by 
degradation, most probably through decarboxylation of 
PAS. CFZNH+-PAS- salts present an increased thermal 
stability in comparison to pure PAS (which decarboxylates 
at 145°C). Decarboxylation of pure PAS can however occur 
at lower temperature but with longer induction period (59 
hours at 74°C, 12.2 hours at 78°C, 5 hours at 90°C23). The 
increased thermal stability observed for all the four forms 
could probably be attributed to the presence of strong 
interactions (charged-assisted H-bonds, as observed in the 
structures of polymorphs I and II) between clofaziminium 
and the carboxylate of PAS. These interactions would 
probably prevent CO2 release from PAS before melting of 
the salt. Such kind of interaction between clofaziminium 
and carboxylate was already reported in several 
studies15,17,40. More particularly improved solubility was 
observed for a clofaziminium mesylate salt presenting the 
same type of interaction15. Furthermore, such kind of strong 
interaction was also shown to improve physical stability of 
amorphous solid dispersion of clofazimine and 
hypromellose phthalate40.   
Pure PAS also decarboxylates in water, however 
decarboxylation of its sodium salt occurs to a lesser extent 
in water thanks to the higher pH of the PAS⋅Na solution in 
comparison to the PAS solution. We believe that the 
preparation of CFZNH+-PAS- could potentially have a 
similar effect and that it could be beneficial for compound 
storage (moisture accelerates PAS decarboxylation and 
higher pH could slower the reaction). This hypothesis is 
supported by the absence of PAS degradation peak on the 
HPLC chromatograms measured after a 24h dispersion of 
CFZNH+-PAS- salts in water.  
Solubility study performed in water indicates a significant 
increase of solubilized CFZ (10.26 ± 0.52 µg/mL (form I), 
12.27 ± 0.32 µg/mL (form II), 7.15 ± 0.43 µg/mL (form III) 
and 8.50 ± 1.24 µg/mL (form IV)) from CFZNH+-PAS- salts 
in comparison to pure CFZ (0.20 ± 0.03 µg/mL). 
Interestingly, forms III and IV have very similar solubility in 
water (same value within experimental errors). 
Furthermore, CFZNH+-PAS- salt preparation prevents PAS 
decarboxylation in water as indicated by the absence of 
degradation peak on the HPLC chromatogram.   
Slurry of all four forms in FaSSGF has shown anion 
exchange and formation of CFZNH+Cl-. In consequence, 
CFZ bioavailability could be reduced because of the 
formation of CFZNH+Cl- in the stomach. Preparation of 
gastro-resistant caps of CFZNH+-PAS- could be an 
alternative, among others, that could potentially avoid or 
reduce PAS decarboxylation and CFZNH+Cl- formation in 
the stomach while maintaining an improved solubility profile 
for CFZNH+-PAS-. 
Competitive slurry experiments performed at 22°C in water 
have shown both the forms I and II are less stable than form 
III which is in accordance with the fact that the latter is less 
soluble than forms I and II in water. The most stable form 
in these conditions is form IV.  
DVS analyses have shown that none of the four presented 
forms is deliquescent. A reversible 3% water sorption is 
however observed for form I, which could correspond to the 
formation of a monohydrated form. Water desorption 
suggests however that this potential hydrated form is not 
stable at low relative humidity. For all the other forms, 
measured water sorption is less than 1% even at 90% 
relative humidity exposure. 
Conclusion  
Four forms of a salt combining clofazimine and 4-
aminosalicylic acid, two antitubercular drugs susceptible to 
be co-administered in patients suffering from XDR-TB, 
were identified by liquid-assisted grinding. Forms I and II 
have been structurally described and their thermal 
properties have been investigated by TGA/DSC. Two other 
forms for which structure could not be determined were 
also discovered. The preparation of these four forms 
resulted in an improved thermal stability towards PAS 
decarboxylation in comparison to pure PAS. This 
stabilization is also observed in water and it can probably 
be attributed to weak basicity of CFZ which increases pH 
of the solution and thus slows down the PAS 
decarboxylation. 
Preparation of CFZNH+-PAS- salt resulted in an important 
increase of solubilized CFZ (50-fold and 60-fold CFZ 
solubility improvement from CFZNH+-PAS-  forms I and II 
and around 40-fold improvement from forms III and IV 
which have same solubility within experimental errors). 
During the solubility test of CFZNH+-PAS- form I, a phase 
transformation in water has been observed with this 
polymorphic form while no phase transformation is 
observed during solubility evaluation for the three other 
forms.  
Competitive slurry experiments have shown that form IV is 
the most stable one in water at 22°C. Form II is more 
soluble than forms III and IV but the latter two are more 
stable in water.  
DVS analyses have shown a 3% water sorption at 90% 
relative humidity exposure for form I. The three other forms 
present a good stability regarding hygroscopicity as no 
significant water sorption is observed during DVS analyses. 
The phase transformation and the reversible water sorption 
observed for form I suggest that this phase could be more 
challenging for further development. The three other forms 
(II, III and IV) are interesting for further investigation but 
care has to be taken regarding phase transformation as 
several forms of CFZNH+-PAS- salts were identified.   
If such combinations of CFZ with PAS could lead to 
improved bioavailability in vivo remains to be determined.  
A gastro-resistant formulation of CFZNH+-PAS- would 
probably be necessary in order to avoid PAS 
decarboxylation and CFZNH+Cl- precipitation in the 
stomach. However, the present study suggests that 
salification of CFZ (BCS II) with PAS (BCS III drug) could 
lead to improved physico-chemical properties of both 
parent APIs. 
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